Delaware is small, dense, and concentrated around a single dominant health system (ChristianaCare). For GLP-1 weight loss patients, that means relatively consistent access in New Castle County, more rural realities downstate in Kent and Sussex, and the same commercial-insurance dynamics that drive prescribing decisions everywhere on the I-95 corridor. This May 2026 guide covers what works for Delawareans starting Wegovy or Zepbound in 2026 – and how Delaware Medicaid, DHSS-administered, is treating obesity medications this year.

Key Takeaways for Delaware (May 2026)

Delaware Medicaid (DHSS) covers GLP-1s for Type 2 diabetes with prior authorization; obesity-only coverage remains case-by-case in 2026.
ChristianaCare dominates statewide obesity medicine and bariatric surgery; Bayhealth and Beebe cover downstate.
LillyDirect Zepbound vials and NovoCare Wegovy run $499/month cash to Delaware addresses.
Delaware participates in IMLC; multi-state telehealth networks can serve Delaware patients with expedited licensure.
Highmark BCBS Delaware and Aetna dominate the commercial market; both cover Wegovy and Zepbound with prior authorization on most large-group plans.

Telehealth services delivering GLP-1 to Delaware

Delaware’s compactness makes both in-person and telehealth care viable for most residents. We verified all six providers’ Delaware coverage in May 2026.

Hims weight loss ships branded Wegovy and Zepbound across Delaware. Good fit for men in Wilmington and the I-95 corridor who want a streamlined telehealth app.

Ro Body uses board-certified obesity-medicine physicians and runs strong prior-auth support for Highmark BCBS Delaware and Aetna employer plans.

See current Hers pricing

Hers mirrors Hims with women-focused intake (PCOS, postpartum, perimenopause). Clean choice for Delaware women.

Henry Meds offers compounded semaglutide and tirzepatide under 503A patient-specific prescribing for cash-pay Delaware patients.

See current Remedy Meds pricing

Remedy Meds typically posts the lowest sticker price among compounded telehealth options serving Delaware.

See current Mochi Health pricing

Mochi Health emphasizes insurance navigation - useful given Delaware's financial-sector commercial-insurance density.

Wegovy and Zepbound pricing in Delaware

Delaware retail pricing tracks national averages. Wilmington financial-sector employer plans often include strong GLP-1 coverage.

LillyDirect Zepbound vials: $499/month for the 2.5mg and 5mg single-dose vials, shipped to Delaware addresses.
NovoCare Wegovy: $499/month cash-pay program in force May 2026.
Highmark BCBS Delaware, Aetna: Wegovy and Zepbound on specialty PDLs with prior authorization on most large-group plans; BMI 30+ or 27+ with comorbidity typical.
Local pharmacies: Acme, Giant, Walgreens, and CVS stock branded GLP-1s statewide.
Cash retail (no manufacturer card): $1,050-$1,350/month.

Delaware Medicaid GLP-1 coverage in 2026

Delaware Medicaid (administered by DHSS) covers semaglutide and tirzepatide for Type 2 diabetes with prior authorization in 2026. Obesity-only coverage of Wegovy and Zepbound remains case-by-case - frequently denied without a qualifying comorbidity. Delaware expanded Medicaid under the ACA, so adult eligibility extends to 138% FPL.

Type 2 diabetes diagnosis with documented A1c.
Step therapy through metformin unless contraindicated.
BMI thresholds (30+ or 27+ with comorbidity) for any obesity-related exception requests.
Quantity limits at FDA-labeled dose escalation.
Reauthorization typically every 6-12 months.

Top healthcare systems for obesity medicine in Delaware

ChristianaCare: Delaware's dominant health system - runs the state's most comprehensive obesity medicine and bariatric surgery program, with ABOM-credentialed clinicians and integrated dietitian and behavioral health services.
Nemours Children's Health: Pediatric and adolescent obesity medicine for Delaware families.
Bayhealth: Kent County anchor with bariatric and medical weight loss services.
Beebe Healthcare: Sussex County coastal anchor - growing weight management bench.

Compounded GLP-1 in Delaware

Post-FDA September 2025 shortage delisting, large-scale 503B compounding wound down. In Delaware in 2026:

503A patient-specific compounding through Delaware-licensed pharmacies with documented clinical justification remains legal.
Delaware Board of Pharmacy enforces USP 797/795 sterility standards.
Non-resident pharmacies shipping compounded GLP-1s into Delaware must hold Delaware non-resident pharmacy licensure.

Delaware telehealth prescribing rules

The Delaware Board of Medical Licensure and Discipline permits telehealth prescribing of GLP-1s with the following 2026 requirements:

The clinician must hold an active Delaware medical license or IMLC compact privilege.
The patient must be physically located in Delaware during the visit.
A documented clinician-patient relationship; synchronous audio-video for initial GLP-1 evaluation is preferred.
Schedule IV anti-obesity drugs (phentermine, phendimetrazine) can be prescribed via telehealth under federal DEA Schedule IV rules and the 2025 telehealth prescribing extension.
Identity verification and current weight/BMI documentation required.

Climate and regional considerations on GLP-1 in Delaware

Delaware's mid-Atlantic climate brings humid summers and mild winters. Coastal humidity at Rehoboth and Bethany Beach combines with GLP-1-related thirst suppression to create dehydration risk during summer beach activity.

Hydrate aggressively during humid summer activity - 80-100 oz/day during heat waves.
Mild Delaware winters permit year-round outdoor walking (especially along the Wilmington Riverwalk and beach boardwalks).
Watch for orthostatic dizziness during dose escalation, especially on hot beach afternoons.
Coastal Sussex County retiree population should integrate cardiology follow-up given common cardiovascular comorbidities.
Wilmington financial-sector sedentary work patterns are a real consideration; structured activity goals improve outcomes.

Cost-saving paths for Delaware residents

Commercial insurance with copay card is the cheapest route for most insured Delaware residents - sometimes $25/month.
NovoCare Wegovy and LillyDirect Zepbound at $499/month cash.
HSA/FSA dollars apply with an Rx - particularly relevant for Wilmington financial-sector employees with HSA-eligible plans.
Delaware Medicaid if you have Type 2 diabetes or qualifying eligibility.
State employee plan (Delaware Statewide Benefits) includes GLP-1 coverage with prior authorization in 2026.
ChristianaCare employer plan covers GLP-1s for qualifying associates.

FAQ - Delaware-specific GLP-1

Will Delaware Medicaid pay for Wegovy in 2026?

For Type 2 diabetes, yes (with prior authorization). For obesity alone, coverage is case-by-case and frequently denied without qualifying comorbidity.

Does Highmark BCBS Delaware cover Zepbound?

Yes, on most large-group plans, with prior authorization documenting BMI and comorbidity. Individual ACA marketplace plans vary.

Can a Philadelphia doctor prescribe me Zepbound while I live in Wilmington?

Only if that clinician holds a Delaware medical license or IMLC compact privilege, and you are in Delaware during the visit.

Is compounded semaglutide legal in Delaware?

Yes, as 503A patient-specific compounding through Delaware-licensed or non-resident-licensed pharmacies with documented clinical justification.

What is the cheapest legal way to get Zepbound in Delaware in 2026?

With commercial insurance and a manufacturer copay card, you can often hit $25/month. Cash-pay: LillyDirect's $499/month single-dose vial program.

Which Delaware pharmacies stock Wegovy?

Acme, Giant, Walgreens, and CVS stock branded GLP-1s statewide. Independent pharmacies in Sussex County may need 48-72 hours to special-order.

Do I need an in-person visit before starting a GLP-1?

No - Delaware Board of Medical Licensure rules permit telehealth initiation with synchronous video and documented intake.

Can ChristianaCare enroll me in a GLP-1 clinical trial?

Yes - ChristianaCare regularly participates in obesity and cardiometabolic trials. Search ClinicalTrials.gov filtered to Newark, DE.

Medical disclaimer and GLP-1 contraindications

This guide is educational and is not medical advice. GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) are contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), and in pregnancy. Discuss your personal history with a licensed clinician before starting any GLP-1 therapy.

Affiliate disclosure: BestMedsHub may earn a commission when you book through telehealth provider links. This does not affect editorial rankings or clinical accuracy.

Sources

Delaware Division of Public Health - obesity and chronic disease surveillance, 2026.
Delaware Medicaid (DHSS) Preferred Drug List, 2026 update.
Delaware Board of Medical Licensure and Discipline - telehealth practice standards.
Delaware Board of Pharmacy - compounding and non-resident pharmacy rules.
FDA prescribing information: Wegovy (semaglutide) and Zepbound (tirzepatide).
Eli Lilly LillyDirect and Novo Nordisk NovoCare program pages.